Skip 
Navigation Link
Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
Primary Care Pharmacy Model Attractive to Patients1991-2014 Saw Minimal Change in Health Spending Per StateLegalized Pot May Lead to More Traffic CrashesMany Doctors Silent on Cost of Cancer CareGroup Urges Tougher Limits on Chemical in Shampoos, Cosmetics18 Percent Increase Projected in Primary Care Demand by 2023Why Patients Leave the Hospital Against Doctor's OrdersRaise the Smoking Age to 21? Most Kids Fine With ThatComprehensive Audiologic Care Feasible in Free Clinic ModelMany Tanning Salons Defy Legal Age Limits on UsersLifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyFDA Puts Brakes on Rule Requiring New 'Nutrition Facts' LabelCardiac Arrest? Someday, Drones May Come to Your RescueSAMHSA: 9.8 Million U.S. Adults Have Serious Mental IllnessFDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From MarketHealth System Sees Success With E-Visits Via Patient PortalOvercharging Common in U.S. Emergency RoomsAdvocating for a Loved OneHigh Costs for Myeloma Patients Not Getting Low-Income SubsidyGetting Bedbugs Out of Nursing Homes, Apartment Buildings - for GoodCosts of ER Treatments a Mystery to Many DocsNew Bill Intends to Repeal Limits on Physician-Owned HospitalsTechnology Can Help Patients Facing Routine DecisionsKidneys From Deceased Diabetics Might Ease Organ Shortage: StudyElements of a Patient-Centered Hospital Room IdentifiedCan Tracking Germs in One Hospital Make All Hospitals Safer?Chances of Successful CPR Dwindle as Seniors AgeNew FDA Head Outlines 'Forceful Steps' Against Opioid CrisisChecking Patient's Drug History May Help Curb Opioid AbuseAt Major Teaching Hospitals, Lower Death RatesAmericans Skeptical of Corporate-Backed Health ResearchToo Many Americans Still Go Without Cancer ScreeningsBlack, Hispanic Americans Less Likely to See a NeurologistSome Lead Poisoning Tests May Be FaultyYour Doctor's Age Might Affect Your CareMany U.S. Travelers Skip Measles Shots, Despite Infection RiskPatients Satisfied With Telehealth Primary Care VisitsNearly a Third of Drugs Hit by Safety Issues After FDA ApprovalNo Routine Screening for Thyroid Cancer: Expert PanelPAS: Internet Info Can Lower Parent Trust in Doctors' DiagnosisFDA Warns of Tattoo DangersBystander CPR Not Only Saves Lives, It Lessens Disability: StudyMore Starring Roles for Booze in Kids' Movies, Study FindsMental Health Myths Abound in the U.S.Half of U.S. Docs Get Payments From Drug, Device Industries: StudyAMA Urges Doctors to Talk About Safe Opioid Storage, DisposalRoutine Blood Tests Can Harm Patient CareApril 29 Is National Prescription Drug Take Back Day
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

FDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From Market

HealthDay News
by -- Robert Preidt
Updated: Jun 9th 2017

new article illustration

FRIDAY, June 9, 2017 (HealthDay News) -- Sales of reformulated Opana ER, a prescription opioid painkiller, should be halted in the United States, the U.S. Food and Drug Administration says.

In its request Thursday for Endo Pharmaceuticals to voluntarily withdraw the drug, the FDA said the benefits of the drug may no longer outweigh the risk of abuse. It's the first time the FDA has moved to take an opioid pain medication off the market due to the public health threat of abuse.

The FDA's analysis of data gathered after the drug was approved showed that injection abuse of reformulated Opana ER (oxymorphone hydrochloride) was linked with a serious outbreak of HIV and hepatitis C, as well as cases of a serious blood disorder called thrombotic microangiopathy.

In March 2017, an FDA advisory committee concluded that the benefits of reformulated Opana ER no longer outweigh its risks.

"We are facing an opioid epidemic -- a public health crisis, and we must take all necessary steps to reduce the scope of opioid misuse and abuse," FDA Commissioner Dr. Scott Gottlieb said in an agency news release.

"We will continue to take regulatory steps when we see situations where an opioid product's risks outweigh its benefits, not only for its intended patient population but also in regard to its potential for misuse and abuse," he added.

Addiction to prescription opioids, which include oxycodone (Oxycontin, Percocet) and hydrocodone (Vicoprofen), is a growing epidemic in the United States. The number of opioid overdose deaths has quadrupled in the past 15 years, health officials report.

Opana ER was first approved in 2006 for the management of moderate-to-severe pain in patients who required an around-the-clock opioid for an extended period of time. In 2012, Endo replaced the original formulation of Opana ER with a new formulation intended to make the drug resistant to physical and chemical manipulation for abuse by snorting or injecting.

However, the FDA has concluded that the reformulation can't meaningfully reduce abuse of the drug.

"The abuse and manipulation of reformulated Opana ER by injection has resulted in a serious disease outbreak. When we determined that the product had dangerous unintended consequences, we made a decision to request its withdrawal from the market," Dr. Janet Woodcock, director of the FDA's Center for Drug Evaluation and Research, said in the news release.

If Endo does not voluntarily remove reformulated Opana ER from the market, the FDA said it would withdraw approval of the drug.

Until Opana ER is taken off the market, the FDA is warning health care professionals and others of the serious risks associated with abuse of the drug.

In a statement, Endo said it's "reviewing the request and is evaluating the full range of potential options."

More information

The U.S. National Institute on Drug Abuse outlines the signs of pain medicine abuse and addiction.